Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.38 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | HPGD | P15428 | 5/20 | 0.34 |
| ▸ | SQOR | Q9Y6N5 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL312753 | 0.90 | CTSS (0.43) | CTSSCTSKPSDKDM4EALDH1A1 | |
| SCHEMBL1924278 | 0.89 | KDM4E (0.46) | CTSSCTSKKDM4EALDH1A1HPGD | |
| SCHEMBL1924168 | 0.86 | ALDH1A1 (0.48) | PSDKDM4EALDH1A1HPGDPOLB | |
| SCHEMBL1925741 | 0.86 | KDM4E (0.46) | CTSSCTSKKDM4EALDH1A1HPGD | |
| SCHEMBL1924221 | 0.86 | KDM4E (0.42) | CTSSPSDKDM4EALDH1A1HPGD | |
| SCHEMBL1924461 | 0.83 | MAPT (0.49) | KDM4EALDH1A1HPGDSQORPOLB | |
| SCHEMBL1924945 | 0.83 | CTSK (0.54) | CTSSCTSKKDM4EALDH1A1TP53 | |
| SCHEMBL1924754 | 0.81 | CTSS (0.42) | CTSSCTSKKDM4EALDH1A1HPGD | |
| SCHEMBL1925694 | 0.81 | CTSS (0.42) | CTSSCTSKPSDKDM4EALDH1A1 | |
| SCHEMBL1924897 | 0.80 | CTSS (0.40) | CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1670801-B1 | PYRAZOLO AND IMIDAZO-PYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-06-08 | — | — | EP | disclosed |
| US-7514443-B2 | Substituted pyrazolo[1,5-a]pyrimidines as inhibitors of metabotropic glutamate receptors | HOFFMANN-LA ROCHE INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20080051421-A1 | Pyrazolo-pyridine | WICHMANN JUERGEN | 2008-02-28 | — | — | US | disclosed |
| US-7329662-B2 | Pyrazolo-pyridine | HOFFMANN-LA ROCHE INC. (US) | 2008-02-12 | — | — | US | disclosed |
| EP-1670801-A1 | PYRAZOLO AND IMIDAZO-PYRIMIDINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| US-20050130992-A1 | Pyrazolo-pyridine | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-16 | — | — | US | disclosed |
| WO-2005040171-A1 | PYRAZOLO AND IMIDAZO-PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130992-A1 | Pyrazolo-pyridine | CHRM2, CHRM1, QDPR | CTSS 2730/4885CTSK 2029/4885PSD 332/4885 |
| US-20080051421-A1 | Pyrazolo-pyridine | CHRM2, CHRM1, QDPR | CTSS 2730/4885CTSK 2029/4885PSD 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.